Clinical analysis assesses early cyclosporine A levels in allogeneic stem cell transplantation recipients, highlighting the need to evaluate graft-versus-host disease risks.
Cyclosporin A (CsA) remains a major component of immunosuppressive regimens applied in allogeneic hematopoietic stem cell transplantation (HSCT). The impact of CsA trough levels during the first weeks after HSCT has not yet been investigated specifically in anti-T-lymphocyte globulin (ATLG)-based HSCT from matched related and unrelated donors.
No takes yet. Share an insight, caveat, or question.
Nikoloudis et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: